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IMM-101 is an immunotherapeutic agent in clinical
development as an adjunctive treatment in cancer. It
comprises heat-killed whole cell Mycobacterium obuense
and is being developed by Immodulon Therapeutics Ltd,
a biopharmaceutical company dedicated to the discovery
and development of immuno-oncology therapies. Cancer
immunotherapy is based on the evidence that the host
immune system, when appropriately modulated, is able
to generate protective responses against malignant cells.
Such responses, including both innate and adaptive
immune components, may affect the establishment,
growth and spread of tumours. Hence, therapies which
boost general immunosurveillance (e.g. bacterial prepara-
tions) through sustained activation of the immune system
provide therapeutic potential. IMM-101 has undergone a
Phase I safety and tolerability trial in melanoma
(NCT01559819), with a number of patients deciding to
continue treatment with IMM-101 (NCT01559818). Two
Phase II trials are ongoing in advanced, inoperable pan-
creatic cancer (NCT01303172) and advanced pre-treated
colorectal cancer (NCT01539824).
Here we describe “A Randomised, Open-Label, Proof-of-
Concept, Phase II Trial Comparing Gemcitabine with and
without IMM-101 in Advanced Pancreatic Cancer”. This
study, investigating the efficacy of IMM-101 as an adjunc-
tive immunotherapy, allows for 12 cycles of treatment over
approximately 12 months. The primary efficacy endpoint
is overall survival but safety and tolerability, clinical signs
and symptoms of disease, progression-free survival and
overall response rate are also recorded. Sera, collected
monthly, are available for measurements of tumour burden
markers, immunological status and relevant mediators, in
an effort to identify potential prognostic factors for future
assessment.
Recruitment to the trial with 22 sites in 5 countries
finished in July 2013 when 142 patients had been
screened and 110 randomised, 75 to the investigational
group and 35 to the control arm in line with the
planned 2:1 active:control ratio. The treatment phase of
the study ended in July 2014, with 12 patients from the
active group and 1 from the control group having com-
pleted 12 cycles of treatment. The remaining patients
withdrew from the study before this time point. Patients
completing the study were invited to enter a follow-on
study, in which they continued to receive IMM-101 and
12, including 1 control patient, were able to do this.
Endpoints will be analysed using the safety and intent-
to-treat analysis sets. Final results, which will reveal
whether patients receiving the IMM-101 immunothera-
peutic product in combination with Gemcitabine have
significantly improved overall survival compared to
those receiving Gemcitabine alone, are expected to be
available early in 2015.
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